The Global Respiratory Care Devices market was valued at more than USD 29.56 Billion in 2025, and expected to reach a market size of more than USD 43.87 Billion by 2031 with the CA
The global respiratory devices market was valued at a significant amount in the most recent base year. It is expected to grow substantially over the forecast period at a steady compound annual growth rate. The growth is driven by a combination of factors including an increasing prevalence of respiratory disorders such as chronic obstructive pulmonary disease, asthma, sleep apnea, and other pulmonary conditions, as well as rising demand for both therapeutic and diagnostic respiratory technologies. North America has historically dominated the respiratory devices market with the largest share, supported by a strong healthcare infrastructure, widespread adoption of advanced technologies, high awareness levels among healthcare providers and patients, and significant healthcare spending that facilitates access to innovative respiratory care solutions. The dominance of this region is also attributed to the large patient population affected by chronic respiratory diseases and robust standards of clinical care that emphasize early diagnosis and intervention in respiratory conditions. Across the globe respiratory devices are defined as equipment that aids in the breathing process by delivering oxygen to patients, supporting ventilation, enabling pulmonary diagnostics, or protecting against harmful airborne particles. The expanding patient base seeking respiratory support has led to increased demand for devices such as positive airway pressure machines, ventilators, oxygen delivery systems, inhalers, nebulizers, spirometers and advanced monitoring tools. Healthcare professionals and caregivers are increasingly adopting these technologies to improve clinical decision making, enhance patient comfort and achieve better health outcomes. According to the research report "Global Respiratory Care Devices Market Outlook, 2031," published by Bonafide Research, the Global Respiratory Care Devices market was valued at more than USD 29.56 Billion in 2025, and expected to reach a market size of more than USD 43.87 Billion by 2031 with the CAGR of 6.98% from 2026-2031. There is an increasing prevalence of respiratory diseases among patients, which is increasing the demand for technologically advanced products in the market. The prominent players operating in the market are focusing on technological advancements in these devices, such as the development of highly reliable and accurate devices, smart inhalers, among others. The key players are also focusing on wearable technology, such as the development of respiratory sensors for the efficient and accurate diagnosis of respiratory diseases among patients. For instance, in June 2024, Aseptika launched the PUFFClicker3, a smart inhaler dose tracker compatible with pressurized metered dose inhalers and dry powder inhalers. There is also an increasing focus on the incorporation of artificial intelligence into respiratory devices, which can help in the accurate diagnosis of respiratory diseases among patients. These devices have a wide range of applications that further improve patient adherence to the treatment of respiratory disorders. According to a 2023 study published by the Nuffield Department of Primary Care Health Sciences at the University of Oxford, technology can provide over 91% accuracy in the diagnosis of respiratory diseases among patients.
to Download this information in a PDF
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download Sample| By Product Type | Therapeutic Devices | |
| Monitoring Devices | ||
| Diagnostic Devices | ||
| Consumables and Accessories | ||
| By Disease Indication | Chronic Obstructive Pulmonary disease (COPD) | |
| Sleep Apnea | ||
| Asthma | ||
| Infectious Diseases | ||
| Other disease Indications (Respiratory Distress Syndrome, cystic Fibrosis) | ||
| By End User | Hospitals | |
| Ambulatory Care Centers (ACCs) | ||
| Home care Settings | ||
| Other End User | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Russia | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| South America | Brazil | |
| Argentina | ||
| Colombia | ||
| MEA | United Arab Emirates | |
| Saudi Arabia | ||
| South Africa | ||
Therapeutic devices are the largest segment in the category of the global respiratory care devices market is due to their essential role in the treatment and management of a wide range of acute and chronic respiratory conditions. The increasing prevalence of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease, sleep apnea, and pneumonia has created a significant demand for devices that provide immediate relief and long-term management solutions. Inhalers and nebulizers are widely used for targeted drug delivery to the lungs, ensuring effective treatment of airway inflammation and bronchoconstriction while minimizing systemic side effects. Ventilators and positive airway pressure devices are critical for patients with severe respiratory distress, sleep apnea, or acute respiratory failure, providing mechanical support to maintain proper oxygenation and ventilation. Oxygen concentrators and oxygen hoods have become essential in hospitals, home care settings, and emergency care units for patients with hypoxemia or other oxygen-deficient conditions. The versatility and wide application of these devices across hospital settings, clinics, and home care have further strengthened their dominance in the market. Technological advancements have improved the efficiency, portability, and ease of use of therapeutic devices, making them more accessible to patients outside traditional hospital environments. Smart ventilators, portable oxygen concentrators, and battery-operated nebulizers allow patients to manage chronic conditions with minimal disruption to daily life, increasing adoption and expanding market size. Additionally, the rising awareness among patients and caregivers about respiratory health, combined with government initiatives to support home healthcare and chronic disease management, has amplified the demand for therapeutic devices. Chronic obstructive pulmonary disease (COPD) is the largest segment in global respiratory care devices market is due to its high prevalence and the continuous need for long-term management and supportive care. The chronic and progressive nature of COPD requires patients to rely on various therapeutic and supportive devices over extended periods, including inhalers, nebulizers, oxygen concentrators, and ventilators. These devices help in alleviating symptoms such as shortness of breath, wheezing, and reduced oxygen levels, improving patient quality of life and reducing hospitalizations. The rising prevalence of risk factors such as smoking, air pollution, occupational hazards, and aging populations has further contributed to the growing number of COPD cases globally, creating sustained demand for respiratory care devices. Patients with COPD often require continuous monitoring and oxygen therapy to prevent exacerbations and complications, which drives the adoption of portable oxygen concentrators and other home-use devices. Technological advancements in respiratory care devices have also enhanced COPD management, with innovations such as smart inhalers, connected nebulizers, and non-invasive ventilation systems enabling personalized treatment and improved adherence to therapy. The awareness among patients and caregivers regarding the importance of early diagnosis and proper disease management has further fueled the demand for COPD-focused respiratory care devices, as these interventions can slow disease progression and improve overall outcomes. The burden on healthcare systems due to COPD-related hospital admissions and emergency visits has prompted healthcare providers to encourage home-based management solutions, which has further increased the reliance on respiratory care devices. Hospitals are the largest segment in the global respiratory care devices market is due to their critical role in providing acute and continuous care for patients with severe and chronic respiratory conditions. Patients with conditions such as chronic obstructive pulmonary disease, asthma, pneumonia, and sleep apnea often require immediate medical attention, specialized interventions, and continuous monitoring, all of which are most effectively provided in hospital settings. Hospitals are equipped with advanced therapeutic devices such as ventilators, positive airway pressure devices, oxygen concentrators, and nebulizers that are essential for supporting patients with severe respiratory distress or acute exacerbations. The presence of trained healthcare professionals including pulmonologists, respiratory therapists, and critical care specialists ensures proper device usage, maintenance, and patient management, which enhances treatment outcomes and drives the adoption of high-end respiratory care equipment. Additionally, hospitals are increasingly adopting technologically advanced devices with features such as smart monitoring, real-time data analytics, and remote connectivity, which improve patient care and workflow efficiency, further reinforcing their demand for respiratory care devices. The rising number of hospital admissions due to respiratory diseases, driven by factors such as air pollution, smoking, aging populations, and viral outbreaks, has created a sustained need for therapeutic and monitoring devices, ensuring continuous procurement and utilization. Hospitals also play a significant role in managing emergency cases and outbreaks, as seen during the COVID-19 pandemic, where ventilators, oxygen therapy systems, and humidifiers were critical in treating large numbers of patients, highlighting their importance in the respiratory care ecosystem.
to Download this information in a PDF
North America is the largest region in the global respiratory care devices market is due to the high prevalence of chronic respiratory diseases and widespread adoption of technologically advanced medical devices. The prevalence of chronic respiratory diseases such as chronic obstructive pulmonary disease, asthma, and sleep apnea is notably high in the region, driven by factors such as aging populations, smoking, air pollution, and lifestyle-related health issues, which has led to a sustained demand for respiratory care devices. Advanced healthcare infrastructure, including specialized hospitals, clinics, and diagnostic centers, enables the efficient adoption and utilization of a wide range of therapeutic and monitoring devices such as ventilators, oxygen concentrators, nebulizers, positive airway pressure devices, and humidifiers. North American consumers and healthcare providers prioritize early diagnosis, continuous monitoring, and effective disease management, which further drive the demand for technologically advanced and patient-friendly respiratory devices. The region also benefits from significant research and development activities, with numerous domestic and multinational companies investing in innovative solutions, including portable and home-use respiratory devices, smart monitoring systems, and connected digital health technologies, which enhance patient compliance and clinical outcomes. Furthermore, government initiatives, supportive reimbursement policies, and health insurance coverage in the United States and Canada encourage the use of respiratory care devices, especially for chronic disease management and home healthcare, thereby expanding the market size. The COVID-19 pandemic has also underscored the critical need for respiratory support equipment in North America, leading to a surge in ventilator demand, oxygen therapy devices, and hospital-based respiratory care solutions, which has reinforced the market’s growth trajectory.
to Download this information in a PDF
• September 2025: electronRx will unveil its pDx app for chronic respiratory disease management at HLTH 2025, providing a mobile assessment device to enable remote monitoring and optimize patient treatment outcomes. • May 2025: ABM Respiratory Care launched a multi-center home care study with Delve Health to evaluate the BiWaze Clear System's impact on respiratory health in bronchiectasis patients over six months. • May 2025 : ResMed acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) specializing in sleep, respiratory, and cardiac conditions. This acquisition strengthened ResMed’s diagnostic capabilities by integrating VirtuOx’s advanced home-based testing services with ResMed’s portfolio of digital health solutions. • March 2025 : Fisher & Paykel Healthcare launched F&P Nova Nasal mask in New Zealand and Australia. Fisher & Paykel Healthcare introduced the F&P Nova Nasal mask, a next-generation CPAP mask designed for comfort and minimal facial contact. • March 2025 : Dräger launched ProAir, an advanced NIOSH-certified Closed Circuit Breathing Apparatus (CCBA). This innovative device was designed to deliver a continuous oxygen supply for up to four hours, offering critical support in hazardous environments where breathable air is limited. • February 2025: Visby Medical announced that it received the U.S. FDA 510 (k) clearance and a CLIA waiver for its point-of-care respiratory test. The Respiratory Health Test is a PCR test measured using a multiplexed molecular device for Flu A&B and SARS-CoV-2. • December 2024: Bedfont Scientific Limited announced a partnership with Tebaba Medical Services to distribute Bedfont’s diagnosis and treatment technology for respiratory and gastrointestinal conditions. NObreath FeNO and Gastrolyzer devices are now available across Africa and the Middle East. • October 2024: Modivcare, Inc. announced a collaboration with Tenovi to deliver Adherium’s Hailie Smart Inhalers for enhanced patient care and chronic respiratory diseases. The collaboration will combine Tenovi’s Cellular Gateway and Modivcare’s chronic condition management service offerings to treat severe asthma and reduce the total cost of care. • May 2024: Medline Industries, Inc. launched Hudson RCI TurboMist, a small-volume nebulizer for medication delivery among patients, with an aim to strengthen its product portfolio. • March 2024: Berry Global launched the BerryHaler, a dual-chamber, dry powder inhaler with a dose counter, to enable the effective delivery of combination drugs among patients. • February 2024: ResMed launched its AirCurve 11 series bilevel positive airway pressure devices in the United States. These devices use IPAP and EPAP. Equipped with advanced digital technology, the AirCurve 11 looks to help healthcare providers treat sleep apnea more effectively and help patients stick to their therapy. • February 2024: Getinge launched its Servo-c mechanical ventilator in India. The mechanical ventilator has lung-protective therapy tools and caters to respiratory care. It also supports the strategy of accessible and cost-effective healthcare solutions for hospitals in India from Getinge. • January 2024: Inspira Technologies OXY B.H.N Ltd. has launched a blood oxygenation disposable kit for its INSPIRA ART medical device series. The kit is also compatible with other life support machines, thereby allowing the company to enter the market for single-use perfusion systems.

We are friendly and approachable, give us a call.